[The combined measles-yellow fever vaccination in African infants aged 6 to 10 months].
The compared tolerance and immunogenicity of vaccines against yellow fever and measles, separately administered or combined, have been evaluated in a group of 319 children from North Cameroon, aged 6-10 months. The clinical tolerance was excellent for both the isolated and the combined vaccines. The seroconversion level is higher after administration of the combined vaccine: 89.9% against 83.5% for measles, 95.8% against 92.6% for yellow fever, but these results are not significantly different. 30 days after vaccination, the antibody titers are higher with the combined vaccine: 215.3 against 156.5 for measles (non significant difference), 34 against 22.6 for yellow fever (highly significant difference). Whatever the vaccination method is, the antibody levels are protecting. It becomes then possible to include the combined vaccination against yellow fever and measles in the EPI of yellow fever endemic countries.
Mouchon
D
D
Centre Pasteur du Cameroun, Annexe de Garoua.
Pignon
D
D
Vicens
R
R
Tu-Ha-Thanh
Tekaia
F
F
Teulières
L
L
Garrigue
G
G
D000367:Age Factors; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002163:Cameroon; D004338:Drug Combinations; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008458:Measles Vaccine / Q000276:immunology*; D008459:Measles virus / Q000276:immunology*; D012737:Sex Factors; D014765:Viral Vaccines / Q000276:immunology*; D015005:Yellow fever virus / Q000276:immunology*
D000914:Antibodies, Viral; D004338:Drug Combinations; D008458:Measles Vaccine; D014765:Viral Vaccines
Etude de la vaccination combinée rougeole-fièvre jaune chez l'enfant African âgé de 6 à 10 mois.